771894 (RX)
| Previous Close | N/A |
| YTD Return | N/A |
| Expense Ratio (net) | N/A |
| Category | N/A |
| Last Cap Gain | N/A |
| Morningstar Rating | N/A |
| Morningstar Risk Rating | N/A |
| Sustainability Rating | N/A |
| Net Assets | N/A |
| Beta (5Y Monthly) | N/A |
| Yield | N/A |
| 5y Average Return | N/A |
| Holdings Turnover | N/A |
| Last Dividend | N/A |
| Average for Category | N/A |
| Inception Date | N/A |
- GlobeNewswire
BioSyent Announces Grant of Restricted Share Units
MISSISSAUGA, Ontario, March 31, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 56,957 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third anniversary of the applicable grant date. About BioSyent Inc. Listed on the TSX
- GlobeNewswire
FAX Capital Corp. Reports Fourth Quarter and 2021 Results
NOT FOR DISSEMINATION IN THE UNITED STATES OR DISTRIBUTION TO U.S. NEWS WIRE SERVICES TORONTO, March 29, 2022 (GLOBE NEWSWIRE) -- FAX Capital Corp. (FAX Capital or the Company) (TSX: FXC) today announced its results for the fourth quarter and full year ended December 31, 2021. All currency figures are Canadian dollars. Despite heightened market volatility in the latter half of the year, the Company performed well in 2021 aided by solid growth in the value of its existing portfolio of investments
